EPS for Jazz Pharmaceuticals plc (JAZZ) Expected At $2.95

October 13, 2018 - By Darrin Black

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) LogoInvestors sentiment increased to 1.52 in 2018 Q2. Its up 0.50, from 1.02 in 2018Q1. It improved, as 25 investors sold Jazz Pharmaceuticals plc shares while 88 reduced holdings. 79 funds opened positions while 93 raised stakes. 54.43 million shares or 4.78% more from 51.95 million shares in 2018Q1 were reported.
Ajo Limited Partnership accumulated 180,580 shares. Comerica Natl Bank reported 2,482 shares. Suntrust Banks Inc has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Fred Alger Management accumulated 6,000 shares. Regions stated it has 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Moreover, Eaton Vance has 0.05% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Cubist Systematic Strategies Limited Liability holds 287 shares or 0% of its portfolio. Chase Inv Counsel holds 3,155 shares. Renaissance Limited Liability invested 0.16% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Principal Fin Grp Inc has invested 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Two Sigma Ltd reported 1,354 shares or 0% of all its holdings. Quantitative Investment Management Ltd Liability Corporation stated it has 23,300 shares or 0.08% of all its holdings. Eqis Cap Management reported 15,061 shares. Gateway Investment Advisers Lc stated it has 0.04% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Northern holds 0.02% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 356,367 shares.

Since April 13, 2018, it had 0 insider purchases, and 19 sales for $6.05 million activity. Another trade for 700 shares valued at $113,890 was made by Young Matthew P. on Monday, September 17. The insider MILLER MICHAEL PATRICK sold 200 shares worth $31,498. COZADD BRUCE C also sold $151,570 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares. The insider Gray Peter sold $126,277. 3,760 shares valued at $620,400 were sold by WILSON KAREN J on Friday, May 11. Another trade for 660 shares valued at $116,563 was sold by O’Keefe Kenneth W.

Analysts expect Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to report $2.95 EPS on November, 6.They anticipate $0.02 EPS change or 0.68 % from last quarter’s $2.93 EPS. JAZZ’s profit would be $178.20 million giving it 13.46 P/E if the $2.95 EPS is correct. After having $3.11 EPS previously, Jazz Pharmaceuticals plc’s analysts see -5.14 % EPS growth. The stock increased 2.21% or $3.44 during the last trading session, reaching $158.82. About 737,796 shares traded or 70.35% up from the average. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 6.65% since October 14, 2017 and is uptrending. It has underperformed by 8.97% the S&P500.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 7 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Jazz Pharmaceuticals had 10 analyst reports since April 30, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, August 8 by Stifel Nicolaus. The firm has “Buy” rating given on Friday, June 1 by RBC Capital Markets. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, July 11. FBR Capital maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Thursday, May 10. FBR Capital has “Buy” rating and $211 target. The firm has “Buy” rating given on Monday, May 7 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Monday, April 30 with “Buy”. The rating was maintained by Citigroup on Tuesday, July 10 with “Buy”. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Outperform” rating given on Wednesday, May 9 by BMO Capital Markets. BMO Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Wednesday, August 8. BMO Capital Markets has “Outperform” rating and $206 target. The firm earned “Buy” rating on Monday, June 25 by FBR Capital.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $9.59 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 22.4 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

More recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Prnewswire.com which released: “Jazz Pharmaceuticals Survey Highlights Significant Impact of Excessive Daytime Sleepiness Related to Sleep Apnea” on October 10, 2018. Also Seekingalpha.com published the news titled: “Jazz settles Xyrem patent dispute with Amneal Pharma; shares up 2% after hours” on October 11, 2018. Investorplace.com‘s news article titled: “5 Safe Stocks to Buy With Low Price-to-Book Ratios” with publication date: October 12, 2018 was also an interesting one.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>